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BACKGROUND: A phase-III trial showed the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/leucovorin
plus oxaliplatin (FOLFOX-6) in terms of efficacy in first-line treatment of metastatic colorectal cancer. A secondary objective was to
compare the quality of life (QoL) and health-care satisfaction of patients.
METHODS: Patients were randomised to receive XELOX (n¼156) or FOLFOX-6 (n¼150) for 6 months. Quality of life and
satisfaction were assessed by the Quality of Life Questionnaire-C30 (QLQ-C30) and Functional Assessment of Chronic Illness
Therapy Chemotherapy Convenience and Satisfaction Questionnaire (FACIT-CCSQ), respectively. Patients completed
questionnaires at baseline, at Cycle3 (C3) and Cycle (C6) (XELOX) or at C4 and C8 visits (FOLFOX-6) and at their final visit.
RESULTS: A total of 245 and 225 patients were assessed using QLQ-C30 and FACIT-CCSQ, respectively. The completion rates were
480%. Global QoL scores did not differ significantly between groups during the study. According to FACIT-CCSQ, XELOX seemed
more convenient (C3/C4, Po0.001; C6/C8, P¼0.009) and satisfactory to patients (C6/C8, P¼0.003) than FOLFOX-6. At the final
visit, XELOX patients spent fewer days on hospital visits (3.3 vs 5.3 days, P¼0.045) and lost fewer hours of work/daily activities (10.2
vs 37.1h lost, P¼0.007).
CONCLUSION: XELOX has a similar QoL profile, but seemed to be more convenient in terms of administration at certain time points
and reduced time lost for work or other activities compared with FOLFOX-6.
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Colorectal cancer (CRC) is one of the commonest cancers
worldwide. It ranks third in terms of incidence (about 1 million
new cases in 2002) after lung and breast cancer and fourth in terms
of mortality (529000 deaths in 2002) (Parkin et al, 2005). In
Europe, CRC is the second most common cause of cancer-related
death (203700 deaths in 2004) after lung cancer (Boyle and Ferlay,
2005). Despite increased awareness about CRC and screening,
about half of the patients still present with, or subsequently
develop, metastatic disease.
Traditionally, 5-fluorouracil (5-FU) with or without leucovorin
(LV) was the only drug used in the palliative treatment of patients
with metastatic colorectal carcinoma (mCRC), but this treatment
was reported to have a limited impact on survival. Recently,
encouraging results have been obtained with capecitabine (Xeloda;
F Hoffmann-La Roche Ltd, Basel, Switzerland), an oral fluoropyr-
imidine (Miwa et al, 1998; Schu ¨ller et al, 2000; Reigner et al, 2001).
In the first-line treatment of mCRC, capecitabine as single-agent
treatment was found to be at least equivalent to bolus 5-FU/LV in
terms of time to disease progression and overall survival (OS), with
higher response rates (Hoff et al, 2001; Van Cutsem et al, 2001;
Cassidy et al, 2002). A series of phase-III studies were subsequently
performed, which showed the non-inferiority of a combination of
oxaliplatin with capecitabine compared with different 5-FU-based
regimens plus oxaliplatin in patients with mCRC (Dı ´az-Rubio et al,
2007; Porschen et al, 2007; Cassidy et al, 2008; Rothenberg et al,
2008). On the basis of these results, capecitabine seemed to be an
alternative to intravenous 5-FU.
In addition to efficacy data, patient quality of life (QoL),
convenience and satisfaction are assuming increasing importance
in the assessment of cancer therapies. Quality of life considerations
are crucial to understanding the impact of cancer on the patient,
especially when treatments are palliative rather than curative
(Payne, 1992). On the basis of the American Society of Clinical
Oncology, European Medicines Agency and Food and Drug
Administration recommendations, health-related Quality-of-Life
(HRQoL) questionnaires should be incorporated as secondary
assessment criteria in controlled clinical trials conducted in
patients with advanced cancers (ASCO, 1996; Beitz et al, 1996;
EMEA, 2005). Among the available QoL questionnaires, the Cancer
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sQuality of Life Questionnaire-C30 (QLQ-C30) was developed and
validated by the European Organisation for Research and
Treatment of Cancer (Fayers and Bottomley, 2002). It has already
been used in more than 3000 studies worldwide and is translated
and validated in 81 languages (EORTC, 2008). Acceptability of
QLQ-C30 is excellent in patients suffering from CRC (Conroy et al,
2002). The module ‘Chemotherapy Convenience and Satisfaction
Questionnaire’ (CCSQ) of the Functional Assessment of Chronic
Illness Therapy (FACIT) Measurement System, a collection of
HRQoL questionnaires related to the management of chronic
illnesses, measures the health-care satisfaction of patients
(Webster et al, 2003; Yost et al, 2005a).
A randomised, open-label, multicentre, phase-III study was
conducted to show the non-inferiority of oxaliplatin plus
oral capecitabine (XELOX) vs FOLFOX-6 (oxaliplatin plus LV,
then intravenous bolus 5-FU, followed by infusional 5-FU)
in terms of efficacy in the first-line treatment of mCRC in France.
In the per-protocol population, XELOX reached a similar
overall response rate, the primary study end point, compared
with FOLFOX-6. In both the per-protocol and intention-to-
treat (ITT) populations, median progression-free survival
(PFS) and median OS were also comparable, providing further
support for the non-inferiority of XELOX vs FOLFOX-6. While
considering safety, a similar proportion of patients discontinued
chemotherapy because of adverse events in both treatment
groups. This trial showed that XELOX and FOLFOX-6 were similar
in terms of efficacy and safety (Ducreux et al, 2007). One of the
secondary objectives of this phase-III study, which is the focus
of this study, was to compare the QoL and health-care satisfaction
of patients receiving either XELOX or FOLFOX-6 in the first-
line treatment of mCRC, on the basis of the QLQ-C30 and
FACIT-CCSQ.
MATERIALS AND METHODS
Study design
This was a phase-III prospective, randomised, multicentre, open-
label trial. It was designed to show the non-inferiority of XELOX vs
FOLFOX-6 in terms of efficacy in the first-line treatment of mCRC.
Assessment of patients’ QoL and health-care satisfaction, as well as
the health economic impact of both treatments, was the secondary
objective. Eligible patients were assigned to a treatment group
according to a centralised, balanced (1:1) and adaptive randomi-
sation procedure. This procedure was based on a minimisation
method with centre, Ko ¨hne predictive factors (Ko ¨hne et al, 2002)
and previous chemotherapy as stratification factors.
Two first-line chemotherapy regimens were tested: the XELOX
regimen in arm 1 and the FOLFOX-6 regimen in arm 2 (Figure 1).
The study comprised a screening visit (baseline) within 14 days
before inclusion visit on Day 1 (just before Cycle 1), a treatment
period and a follow-up period (including a study visit every 3
months) until the cutoff date, which was fixed at 18 months after
the last patient’s inclusion. Treatments were continued for 24
weeks (up to 8 cycles with XELOX or 12 cycles with FOLFOX-6) or
until disease progression, whichever came first. Study treatment
was discontinued in patients experiencing prolonged toxicity (43
weeks). Dose modifications were made according to previous
publications (Cassidy et al, 2004, 2006).
Patients were randomised between May 2003 and August 2004
and followed up for 18 months until clinical cutoff in December
2006. The total study duration was 47 months. The study was
conducted in France at 33 oncology centres and carried out in
accordance with the Declaration of Helsinki and Good Clinical
Practice Guidelines. An Independent Ethics Committee approved
the protocol. Written informed consent was obtained from all
patients participating in the study.
Patient population
Adult patients (at least 18 years of age) with previously untreated,
histologically proven mCRC (at least one measurable target lesion
using Response Evaluation Criteria In Solid Tumors) (Therasse
et al, 2000), an Eastern Cooperative Oncology Group performance
status p2 and a life expectancy of 43 months were eligible.
Moreover, patients were required to have normal renal function
and adequate haematological and hepatic function. Patients with
rectal cancer and distant metastases, who had previously received
preoperative irradiation on the primary tumour, were eligible if
they had assessable non-irradiated metastases. Pregnant or breast-
feeding women were excluded. Patients who had received
neoadjuvant therapy within the last 6 months containing
oxaliplatin, 5-FU or capecitabine, or patients with a history of
neuropathy, or uncontrolled congestive heart failure, angina
pectoris, hypertension or myocardial infarction within the last 12
months were excluded.
HRQoL measures
Assessment of HRQoL was based on QLQ-C30 (version 3)
(EORTC, 2008) and the CCSQ module from the FACIT scale (Yost
et al, 2005a). The QLQ-C30 has been previously shown to be a
reliable and valid measure of the QoL of cancer patients in
multicultural clinical research settings (Aaronson et al, 1993). The
FACIT-CCSQ convenience items were worded to capture patients’
expectations of chemotherapy and took into account patients’
experience of chemotherapy, satisfaction items and patients’ use of
health-care resources within the previous cycle. Both question-
naires were validated in the French language (Conroy et al, 2004;
Rotonda et al 2008; www.facit.org).
Both QLQ-C30 and FACIT-CCSQ were self-administered by
patients enrolled into the study at baseline and at similar time
points in both groups during the treatment period. Quality of life
assessments were carried out at the same time as tumour imaging
assessments and only during the treatment period, that is, at
baseline, at Cycle 3 (C3) and Cycle 6 (C6) visits (XELOX) or Cycle 4
(C4) and Cycle 8 (C8) visits (FOLFOX-6) and final visit (Day 169).
The timing schedule of QoL and satisfaction assessments is
presented in Figure 2.
The QLQ-C30 used was a past week time-framed questionnaire,
including 30 items and 15 independent subscores. At each QLQ-
C30 assessment, five functional scales (physical, role, cognitive,
Randomisation
ITT (n=306)
Oxaliplatin: 130 mg m
–2,
2-h intravenous
infusion, Day 1
Capecitabine: 1000 mg m
–2
oral, twice a Day 
on Days 1 to 14
21-Days duration, every 3
weeks, up to 8 cycles
Arm 1
XELOX (n=156)
Arm 2
FOLFOX-6 (n=150)
Oxaliplatin: 100 mg m
–2,
2 h intravenous
infusion, Day 1
5-FU: 400 mg m–2, intravenous
bolus injection, Day 1
5-FU: 2400-3000 mg m
–2, 46-
h continuous infusion, on 
Days 1 – 2
14-Day duration, every 2
weeks, up to 12 cycles
LV: 400 mg m–2, 2 h
infusion, Day 1
Figure 1 Study treatment schema. 5-FU, 5-fluorouracil; LV, leucovorin.
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semotional and social), a global QoL scale and nine symptom/item
scales (fatigue, nausea and vomiting, pain, dyspnoea, sleep
disturbance, appetite loss, constipation, diarrhoea and financial
difficulties) were completed. Each was converted into a scale
ranging from 0 to 100. For the QLQ-C30, higher scores represent a
better health state for the five functional scales and for the global
QoL scale, whereas lower scores represent a better health state for
the symptom/item scores. The self-administered FACIT-CCSQ
consists of 15 qualitative items relating to the patient’s experience
of chemotherapy and treatment without time limitations (except
one past week time-framed item) and eight items (quantitative
criteria) relating to the patient’s use of health-care resources
during the previous cycle. Most of the qualitative items were
organised into three subscales related to chemotherapy conve-
nience, concerns and satisfaction. Each scale and item was
transformed into a scale ranging from 0 to 100. The FACIT-CCSQ
was translated into the French language according to the FACIT
procedure.
MID
The minimally important difference (MID) is defined as the
smallest difference in score in the domain of interest that patients
perceive as important, either beneficial or harmful, and that would
lead the clinician to consider a change in the patient’s management
(Guyatt et al, 2002; Yost et al, 2005b). Considering the QLQ-C30,
an MID of more than 10 points from baseline to a subsequent visit
could be considered as being clinically significant (Osoba et al,
1998). Considering the FACIT-CCSQ, the MID was fixed at 6–9
points for convenience, 7–10 points for concerns and 5–9 points
for satisfaction subscales (Yost et al, 2005a).
Statistical methods
The ITT population included all randomised patients meeting the
inclusion criteria. Two HRQoL sets were considered:
  QLQ-C30 set: defined as all ITT patients having an assessable
QLQ-C30 (o50% of missing responses) at baseline,
  FACIT-CCSQ set: defined as all ITT patients having an
assessable FACIT-CCSQ (o50% of missing responses) at
baseline.
The number of required patients in the study was based on
the demonstration of non-inferiority in terms of efficacy
between the XELOX and FOLFOX-6 arms. The total number of
patients needed for randomisation in the per-protocol population
was defined as 137 persons per group. When considering that
10% of patients could be excluded from the study, an
ITT population of (137 2)/0.9¼304 patients was required.
The same number of patients was considered for the secondary
objectives, including QoL and satisfaction assessments. Efficacy
and safety assessments, as well as health economic results, are
presented in detail in separate papers (Perrocheau et al, 2009;
Ducreux et al, 2007).
At each assessment time, the 15 scales of the QLQ-C30 were
computed and analysed in the QLQ-C30 set, whereas the items of
the FACIT-CCSQ were analysed in the FACIT-CCSQ set. For both
questionnaires, missing items were estimated according to their
respective scoring manuals when feasible (Fayers et al, 2001;
www.facit.org). For each item of both questionnaires, the baseline
value and values at subsequent visits were provided for each study
arm using descriptive statistics. The differences between arms were
tested with an analysis of variance test.
Multivariate analyses of OS and PFS were performed using a Cox
model with a non-inferiority margin for the hazard ratio fixed at
1.75 and a power of 90%. The analyses included several variables
such as age, Ko ¨hne score, time interval between CRC diagnosis and
metastatic disease, type of cancer, QoL and health-care satisfac-
tion. Differences in QoL and morbidity were analysed using
analysis of variance, accounting for differences in survival between
groups. Mortality was compared using Kaplan–Meier curves and
log–rank statistics. The primary analysis of QoL data was
performed using a mixed-models analysis of variances for repeated
measures.
The reliability of the multi-item scales of QLQ-C30 and FACIT-
CCSQ was assessed using Cronbach a coefficient for internal
consistency (Cronbach, 1951). A Cronbach a coefficient 40.5 was
considered as acceptable reliability, whereas a Cronbach a
coefficient 40.7 was considered as good reliability (Nunally and
Berstein, 1994).
RESULTS
Study population
A total of 306 patients were randomised: 245 patients (XELOX
n¼126, FOLFOX-6 n¼119) answered the QLQ-C30 and 225
patients (XELOX n¼111, FOLFOX-6 n¼114) answered FACIT-
CCSQ. The characteristics at baseline of these patients are
presented in Table 1. No significant differences between XELOX
and FOLFOX-6 groups regarding socio-demographic data, mCRC
characteristics and other baseline characteristics were observed in
the HRQoL sets.
QoL results
Completion rate The completion rate of QoL assessments
referred to the number of patients participating at the related
visit. Overall, completion rates were satisfactory at the different
visits, and were 480% for both questionnaires and for treatment
groups.
XELOX
FOLFOX
8 cycles of 21 days
HRQol assessment
12 cycles of 14 days
HRQoL assessment
C1 C2 C3 C4 C5 C6 C7 C8
C12 C11 C10 C9 C8 C7 C6 C5 C4 C3 C2 C1
0 246 8 10 12 14 16 18 20 22 24 Weeks
VF
VF
Figure 2 Questionnaires assessment schedule. Each red arrow corresponds to a questionnaire delivery. VF is final visit. The colour reproduction of the
figure is available on the html full text version of the paper.
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sMissing item rate The missing item rate referred to the number
of missing items of data among received forms at the related visit.
Overall, the missing item rates for both questionnaires were not
significantly different between XELOX and FOLFOX-6 at baseline
and at subsequent visits.
The European Organisation for Research and Treatment of Cancer
QLQ-C30 scores No relevant differences were observed between
the FOLFOX-6 and XELOX arms at baseline and at subsequent
visits. Compared with the FOLFOX-6 group, patients had
significantly less dyspnoea in the XELOX group (18.0 (13.9;
22.1)90% vs 25.4 (20.9; 29.8)90%; P¼0.017), but significantly more
sleep disturbances (38.4 (33.3; 43.5)90% vs 29.1 (24.4; 33.7)90%;
P¼0.036) at baseline. For all subsequent evaluations (C3/C4, C6/
C8 and final visit), the QLQ-C30 functional and symptom scores
were not significantly different between the XELOX and FOLFOX-6
arms. Results of the QLQ-C30 are summarised in Table 2.
Moreover, when focusing on sleep disturbances and dyspnoea
items, there were no clinically relevant changes between baseline
and final visit for either group, as the changes in scores were o10.
FACIT-CCSQ scores No relevant differences between groups were
observed at baseline in the FACIT-CCSQ scales. Compared with
the FOLFOX-6 group, patients in the XELOX group reported
significantly better chemotherapy convenience at C3/C4 (74.7
(71.5; 77.9)90% vs 63.0 (59.2; 66.7)90%; Po0.001) and C6/C8 (73.5
(69.6; 77.3)90% vs 65.9 (62.3; 69.4)90%; P¼0.009), as well as better
chemotherapy satisfaction at C6/C8 (79.4 (75.3; 83.6)90% vs 71.2
(67.3; 75.1)90%; P¼0.003) (Figure 3). At the final visit, XELOX
patients spent fewer days on hospital visits (3.3 days (1.5; 5.1)90%
vs 5.3 days (3.4; 7.1)90%; P¼0.045) and saved more hours of work
or usual daily activities (10.2h lost (3.5; 16.9)90% in the XELOX
group vs 37.1h lost (17.4; 56.8)90% in the FOLFOX-6 group,
P¼0.007). No other significant differences between groups were
shown for this questionnaire. Results of FACIT-CCSQ are
summarised in Table 3.
Moreover, as the MID reached more than 6 points for
convenience and more than 5 points for the satisfaction subscales
(Yost et al, 2005a), the differences observed between the XELOX
and FOLFOX-6 groups could be considered as clinically relevant
for satisfaction with XELOX at C6/C8, as well as for convenience
with XELOX at C3/C4 and C6/C8 visits.
Multivariate analysis
The results of multivariate analyses showed that all items of the
QLQ-C30 had a significant correlation with PFS (except for the
cognitive scale, emotional scale and financial difficulties item) and
OS (except for the financial difficulties item).
The FACIT-CCSQ items had no correlation with PFS. Only the
global quality-of-life score of FACIT-CCSQ had a significant
correlation with OS.
Reliability of scales
All QLQ-C30 multi-item scales, except for the cognitive functional
scale at the final visit, showed at least acceptable reliability (data
not shown). The Cronbach a coefficients for the multi-item scales
of FACIT-CCSQ showed good reliability on an average and at least
acceptable reliability (data not shown).
DISCUSSION
This study was the first clinical trial to use both the European
Organisation for Research and Treatment of Cancer QLQ-C30 and
CCSQ module from FACIT to assess patient QoL and satisfaction
with first-line treatment of mCRC. The objective of this study was
to evaluate patients’ QoL and health-care satisfaction in the
XELOX and FOLFOX-6 groups. Patients in the XELOX group
reported significantly better convenience at C3/C4 and C6/C8
visits, as well as better satisfaction at C3/C4, than did patients in
the FOLFOX-6 group according to FACIT-CCSQ. Moreover,
XELOX patients spent fewer days on hospital visits and saved
more hours of work or activity time at the final visit. No
differences between groups were shown using QLQ-C30, but the
Table 1 Baseline demographic characteristics of patients
EORTC QLQ-C30 FACIT-CCSQ
XELOX group
N¼126
FOLFOX-6 group
N¼119 P-value
XELOX group
N¼111
FOLFOX-6 group
N¼114 P-value
Age (years) nmissing 0 0 0.59 0 0 0.47
Mean (s.d.) 65.8 (10.0) 65.6 (8.9) 66.0 (9.8) 65.4 (9.4)
Gender nmissing 0 0 0.20 0 0 0.10
Male n (%) 81 (64.3) 67 (56.3) 74 (66.7) 64 (56.1)
Female n (%) 45 (35.7) 52 (43.7) 37 (33.3) 50 (43.9)
BMI (kgm
 2) nmissing 3 4 0.27 2 4 0.57
Mean (s.d.) 24.6 (4.2) 25.3 (4.9) 24.5 (4.1) 25.1 (5.0)
Localisation in France
a nmissing 0 0 0.08 0 0 0.06
Paris n (%) 9 (7.1) 21 (17.6) 9 (8.1) 22 (19.3)
Northwest n (%) 48 (38.1) 37 (31.1) 34 (30.6) 25 (21.9)
Northeast n (%) 33 (26.2) 31 (26.1) 31 (27.9) 31 (27.2)
Southeast n (%) 25 (19.8) 25 (21.0) 23 (20.7) 28 (24.6)
Southwest n (%) 11 (8.7) 5 (4.2) 14 (12.6) 8 (7.0)
ECOG PS nmissing 0 0 0.89 0 0 0.76
0–1 n (%) 116 (92.1) 109 (91.6) 101 (91.0) 105 (92.1)
2 n (%) 10 (7.9) 10 (8.4) 10 (9.0) 9 (7.9)
Tumour primary site nmissing 0 0 0.43 0 0 0.54
Colon n (%) 76 (60.3) 75 (63.0) 66 (59.5) 69 (60.5)
Colorectum n (%) 28 (22.2) 30 (25.2) 26 (23.4) 31 (27.2)
Rectum n (%) 22 (17.5) 14 (11.8) 19 (17.1) 14 (12.3)
Abbreviations: BMI¼body mass index; CCSQ¼Chemotherapy Convenience and Satisfaction Questionnaire; ECOG PS¼Eastern Cooperative Oncology Group performance
status; EORTC¼European Organisation for Research and Treatment of Cancer; FACIT¼Functional Assessment of Chronic Illness Therapy; N¼number of exposed patients;
QLQ-C30¼Quality of Life Questionnaire-C30.
aThese five French areas correspond to the areas defined by the five area codes (01, 02, 03, 04 and 05).
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sTable 2 EORTC QLQ-C30 questionnaire assessment in the QLQ-C30 set (N¼245)
XELOX group, n¼126 FOLFOX-6 group, n¼119
EORTC QLQ-C30 n MV (%) Mean (s.d.) n MV (%) Mean (s.d.) *P-value
Physical functioning (%)
Baseline 126 0.0 80.7 (20.2) 118 0.8 79.1 (21.9) 0.952
C3/C4 98 0.0 80.5 (22.0) 96 1.0 78.9 (19.0) 0.225
C6/C8 78 0.0 80.0 (18.5) 72 2.7 79.5 (18.6) 0.645
Final visit 63 0.0 75.9 (22.0) 65 0.0 74.9 (21.0) 0.631
Role functioning (%)
Baseline 124 1.6 71.2 (31.8) 116 2.5 68.2 (32.3) 0.484
C3/C4 98 0.0 73.8 (28.7) 96 1.0 67.4 (30.6) 0.121
C6/C8 78 0.0 74.8 (28.9) 73 1.4 70.5 (27.0) 0.198
Final visit 62 1.6 69.9 (32.1) 65 0.0 65.1 (29.4) 0.206
Cognitive functioning (%)
Baseline 123 2.4 83.7 (20.5) 118 0.8 83.2 (22.2) 0.961
C3/C4 98 0.0 85.0 (19.9) 96 1.0 82.3 (20.5) 0.247
C6/C8 78 0.0 79.3 (23.1) 74 0.0 82.0 (19.3) 0.641
Final visit 63 0.0 78.6 (19.3) 64 1.5 77.7 (19.5) 0.631
Emotional functioning (%)
Baseline 124 1.6 68.8 (25.2) 117 1.7 68.0 (24.5) 0.715
C3/C4 98 0.0 78.6 (20.2) 96 1.0 75.2 (22.0) 0.333
C6/C8 78 0.0 79.2 (20.4) 74 0.0 75.6 (21.9) 0.285
Final visit 62 1.6 72.7 (23.8) 64 1.5 69.7 (24.2) 0.438
Social functioning (%)
Baseline 123 2.4 77.2 (30.1) 116 2.5 76.1 (27.6) 0.461
C3/C4 98 0.0 79.3 (24.8) 96 1.0 72.9 (26.2) 0.058
C6/C8 78 0.0 78.8 (25.4) 74 0.0 78.2 (25.3) 0.924
Final visit 63 0.0 73.5 (28.7) 64 1.5 71.6 (27.0) 0.539
Global quality of life scale (%)
Baseline 123 2.4 62.4 (22.8) 116 2.5 59.8 (20.9) 0.372
C3/C4 98 0.0 66.5 (22.2) 96 1.0 62.2 (18.0) 0.050
C6/C8 78 0.0 64.5 (21.7) 73 1.4 62.7 (19.0) 0.349
Final visit 63 0.0 58.1 (22.8) 63 3.1 60.4 (19.1) 0.449
Fatigue (%)
Baseline 125 0.8 40.3 (29.1) 117 1.7 38.4 (27.6) 0.626
C3/C4 98 0.0 36.9 (24.9) 97 0.0 40.3 (26.9) 0.510
C6/C8 78 0.0 38.1 (27.5) 73 1.4 40.3 (26.9) 0.536
Final visit 63 0.0 45.1 (27.2) 65 0.0 41.5 (25.9) 0.475
Nausea and vomiting (%)
Baseline 125 0.8 6.0 (14.9) 118 0.8 8.2 (19.5) 0.395
C3/C4 98 0.0 11.9 (19.6) 97 0.0 12.2 (22.2) 0.738
C6/C8 78 0.0 10.5 (17.8) 73 1.4 13.0 (21.2) 0.687
Final visit 63 0.0 10.3 (18.3) 65 0.0 10.3 (17.6) 0.991
Pain (%)
Baseline 126 0.0 23.3 (27.8) 118 0.8 24.0 (27.6) 0.707
C3/C4 98 0.0 19.0 (24.5) 97 0.0 18.7 (23.0) 0.949
C6/C8 78 0.0 20.9 (28.9) 74 0.0 17.3 (20.0) 0.908
Final visit 63 0.0 31.2 (33.5) 65 0.0 25.4 (26.4) 0.512
Dyspnoea (%)
Baseline 123 1.6 18.0 (27.3) 117 1.7 25.4 (28.9) 0.017
C3/C4 97 1.0 18.6 (25.9) 95 2.1 18.6 (24.7) 0.890
C6/C8 77 1.3 18.6 (25.6) 73 1.4 19.2 (24.8) 0.774
Final visit 62 1.6 21.0 (27.1) 65 0.0 20.0 (24.9) 0.974
Insomnia (%)
Baseline 125 0.8 38.4 (34.1) 117 1.7 29.1 (30.2) 0.036
C3/C4 98 0.0 26.5 (31.4) 97 0.0 25.4 (29.6) 0.916
C6/C8 78 0.0 25.6 (31.7) 72 2.7 20.4 (26.6) 0.391
Final visit 63 0.0 28.6 (33.3) 65 0.0 24.6 (27.2) 0.725
Appetite loss (%)
Baseline 125 0.8 24.3 (32.9) 116 2.5 26.1 (33.4) 0.550
C3/C4 98 0.0 21.4 (29.2) 97 0.0 24.4 (34.2) 0.798
C6/C8 78 0.0 23.5 (30.4) 73 1.4 19.4 (28.4) 0.424
Final visit 62 1.6 31.2 (36.1) 63 3.1 20.6 (30.8) 0.106
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sFACIT-CCSQ highlighted that patients seemed more satisfied in
the XELOX group than in the FOLFOX-6 group at certain time
points. The assessment of internal reliability, based on Cronbach a
coefficients, revealed a good level of construct validity of both
questionnaires.
No clinically relevant differences in QoL between groups were
shown using QLQ-C30. This result is not surprising, as XELOX and
FOLFOX-6 have similar safety and efficacy profiles (Ducreux et al,
2007). Our study showed that the FACIT-CCSQ assessment showed
a significant difference between the two treatment regimens in
days for hospital visits and hours lost for work or other activities.
However, no difference was found between the two regimens in
any of the measures for ‘functioning’ in the QLQ-C30 assessment.
This could be partly explained by the fact that patients answered
the QLQ-C30 just before their hospital visit. Moreover, the
assessment related to the previous week when the patient did
not receive any chemotherapy. Multivariate analyses showed a
significant correlation between most of the QLQ-C30 items and
PFS, as well as OS. These results are consistent with those of other
studies. Indeed, it has been shown that several QLQ-C30 scales
have prognostic value for survival in mCRC (Efficace et al, 2006;
Efficace et al, 2008).
The assessment of QoL and satisfaction of mCRC patients was a
secondary objective of this clinical trial. In this context, these data
have some limitations. The baseline QLQ-C30 profiles were similar
in the XELOX and FOLFOX-6 arms, except for dyspnoea and sleep
disturbances. Patients had significantly less dyspnoea and more
sleep disturbances in the XELOX group than in the FOLFOX-6
group at baseline, although these differences were not clinically
relevant as the differences in scores were less than the MID of 10
points. When considering the changes from baseline to final visit,
these between-group differences were no longer evident. Finally,
completion rates and item missing rates at different time
points were not different between study arms, providing further
support for the comparability of treatment groups. The decrease in
the number of patients at subsequent visits was similar in
both groups and could be partly explained by the patient’s
tumour status.
Despite these limitations, the results are consistent with other
QoL and patient preference studies of oral fluoropyrimidines vs
intravenous 5-FU/LV in CRC. First, a series of studies have shown
the preference of patients for oral treatment (Borner et al, 2002;
Kopec et al, 2007). For example, Kopec et al (2007) showed
similar results in patients with stage II/III carcinoma of the
Table 2 (Continued)
XELOX group, n¼126 FOLFOX-6 group, n¼119
EORTC QLQ-C30 n MV (%) Mean (s.d.) n MV (%) Mean (s.d.) *P-value
Constipation (%)
Baseline 124 1.6 17.2 (29.6) 117 1.7 18.5 (26.8) 0.312
C3/C4 95 3.1 13.0 (21.4) 95 2.1 21.1 (28.8) 0.065
C6/C8 77 1.3 19.0 (27.3) 73 1.4 14.6 (24.8) 0.286
Final visit 61 3.2 22.4 (31.5) 64 1.6 21.4 (28.1) 0.860
Diarrhoea (%)
Baseline 124 1.6 16.7 (26.0) 116 2.5 15.8 (26.2) 0.700
C3/C4 98 0.0 21.1 (28.1) 96 1.0 21.2 (30.3) 0.800
C6/C8 77 1.3 21.2 (31.5) 74 0.0 16.2 (25.4) 0.506
Final visit 63 0.0 15.9 (27.3) 64 1.6 7.8 (18.5) 0.072
Financial difficulties (%)
Baseline 123 2.4 8.9 (23.4) 114 4.2 10.8 (24.5) 0.515
C3/C4 98 0.0 7.1 (19.3) 95 2.1 9.1 (20.9) 0.477
C6/C8 78 0.0 8.5 (21.8) 74 0.0 11.3 (24.2) 0.289
Final visit 63 0.0 10.1 (22.1) 64 1.6 12.0 (22.5) 0.479
Abbreviations: C3, C4, C6, C8¼Cycles 3, 4, 6 and 8; EORTC¼European Organisation for Research and Treatment of Cancer; %MV¼percentage of missing values; QLQ-
C30¼Quality of Life Questionnaire-C30. *P value: Student’s t-test or Wilcoxon test for independent samples. Bold values indicate Po0.05.
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Figure 3 FACIT-CCSQ assessment of chemotherapy convenience and
satisfaction in patients receiving either XELOX or FOLFOX-6. CCSQ,
Chemotherapy Convenience and Satisfaction Questionnaire; FACIT,
Functional Assessment of Chronic Illness Therapy.
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scolon who received oral uracil/ftorafur (UFT) plus LV or standard
intravenous 5-FU/LV as adjuvant chemotherapy. Health-related
Quality-of-Life was measured with the Functional Assessment of
Cancer Therapy-Colorectal (FACT-C), the Short Form-36 Vitality
Scale and a Quality of Life Rating Scale. Patients perceived
adjuvant treatment with UFT/LV as being more convenient than
standard IV treatment with 5-FU/LV. Both regimens were well
tolerated and did not differ in their impact on HRQoL. Moreover,
two recent studies underlined the preference of patients for
capecitabine over 5-FU. Pelusi (2006) confirmed that the oral
approach was preferred by patients because of its convenience
(fewer medical office visits, no intravenous access required) and
by clinicians because it eliminated the risk of complications,
such as infection and clotting associated with venous access
Table 3 FACIT-CCSQ questionnaire assessment in the FACIT-CCSQ set (N¼225)
XELOX group, n¼111 FOLFOX-6 group, n¼114
FACIT-CCSQ n MV (%) Mean (s.d.) n MV (%) Mean (s.d.) *P-value
Chemotherapy convenience
Baseline 111 0.0 54.9 (23.3) 112 1.8 53.2 (19.1) 0.471
C3/C4 93 0.0 74.7 (18.5) 88 0.0 63.0 (21.0) o0.001
C6/C8 65 1.5 73.5 (18.6) 72 0.0 65.9 (18.2) 0.009
Final visit 61 0.0 71.9 (19.2) 63 0.0 66.2 (18.0) 0.081
Chemotherapy concerns
Baseline 111 0.0 61.4 (19.3) 113 0.9 58.9 (19.8) 0.492
C3/C4 93 0.0 76.3 (19.6) 88 0.0 72.7 (20.6) 0.186
C6/C8 66 0.0 75.3 (19.8) 72 0.0 73.9 (17.7) 0.454
Final visit 61 0.0 71.6 (19.7) 62 1.6 67.6 (19.9) 0.289
Chemotherapy satisfaction
Baseline — — — — — — —
C3/C4 84 10.7 74.1 (21.9) 79 11.4 72.0 (20.0) 0.311
C6/C8 63 4.8 79.4 (19.7) 66 9.1 71.2 (18.9) 0.003
Final visit 52 17.3 71.2 (20.5) 55 14.5 67.6 (20.2) 0.296
I worry that my chemotherapy will not be effective (%)
Baseline 108 2.7 74.8 (29.3) 110 3.6 77.3 (25.7) 0.707
Final visit 60 1.6 73.8 (30.3) 60 5.0 76.7 (26.4) 0.751
My chemotherapy schedule is stressful to my family (%)
Baseline 110 0.9 54.5 (29.6) 114 0.0 57.0 (28.3) 0.571
Final visit 61 0.0 69.3 (30.1) 61 3.3 69.3 (25.2) 0.703
Within past week
I am content with the quality of my life right now (%)
Baseline 107 3.7 52.3 (28.0) 109 4.6 50.7 (26.2) 0.553
Final visit 58 5.2 46.1 (28.4) 59 6.8 45.3 (23.0) 0.711
Within past cycle
Hospital visits
Final visit 39 36.1 1.9 (4.5) 40 36.5 2.1 (4.6) 0.974
Emergency room admissions
Final visit 31 49.2 0.0 (0.0) 33 47.6 0.0 (0.0) 1.000
Physician visits
Final visit 38 60.4 0.6 (1.7) 37 41.3 0.3 (1.0) 0.295
Number of days for a usual hospital visit
Final visit 31 49.2 3.3 (5.9) 27 57.1 5.3 (5.6) 0.045
Number of hours for a usual emergency room admission
Final visit 22 63.9 0.2 (0.9) 17 73.0 0.5 (1.5) 0.426
Number of hours for a usual physician visit within past cycle?
Final visit 27 55.7 0.6 (1.0) 26 58.7 1.4 (5.9) 0.407
How many hours have you lost for your work or usual daily activities?
Final visit 33 45.9 10.2 (22.6) 34 46.0 37.1 (67.9) 0.007
How many hours have your friends or your family lost for their work or usual daily activities?
Final visit 36 41.0 3.1 (4.6) 32 49.2 20.0 (53.0) 0.059
Abbreviations: C3, C4, C6, C8¼Cycles 3, 4, 6 and 8; CCSQ¼Chemotherapy Convenience and Satisfaction Questionnaire; FACIT¼Functional Assessment of Chronic Illness
Therapy; %MV¼percentage of missing values. *P-value: Student’s t-test or Wilcoxon test for independent samples. Bold values indicate Po0.05.
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sdevices and infusion pumps. In another study conducted by
Twelves et al (2006), 97 patients with previously untreated
advanced or mCRC were randomised to receive capecitabine,
followed by intravenous 5-FU/LV (Mayo Clinic, in-patient de
Gramont or outpatient modified de Gramont regimens), or
intravenous 5-FU/LV followed by capecitabine. Quality of life
was assessed with the FACT-C questionnaire. The results
confirmed that the majority of patients with mCRC preferred oral
therapy.
Health economic results based on the current clinical trial
further showed that XELOX significantly decreased the direct
treatment costs of mCRC patients, as well as hospital resource
consumption, in comparison with FOLFOX-6 (Perrocheau et al,
2009). Considering clinical and economic impacts, the XELOX
regimen seems to be a relevant alternative to FOLFOX-6 in the
first-line treatment of mCRC.
CONCLUSION
This study was the first clinical trial to evaluate QoL and health-
care satisfaction in patients receiving XELOX in the first-line
treatment of mCRC. XELOX has a similar QoL profile, but seems to
be more convenient in terms of administration at certain time
points and reduced time lost for work or other activities compared
with FOLFOX-6. Therefore, capecitabine, used in the XELOX
regimen, clearly represents an effective and well-tolerated oral
alternative to intravenous 5-FU/LV.
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